Venturis is unable to acknowledge its horrific missteps. Instead all we get from this company and its supporters (i.e. company management putting out information not under their own names) is deflection, finger-pointing, false statements, and constantly looking backward and blaming someone who left 7 years ago. Isn't that pathetic - to only be blaming someone who hasn't been inside the company in 7 years? It shows a remarkable lack of accountability, honesty, integrity, and a lot else.
Here are the subjects Venturis Therapeutics (formerly Cardiovascular Biotherapeutics or CVBT) will NEVER touch:
1) Why has the company been telling us every single year since 2017 that the clinical trials are about to re-start "next year," yet next year comes and goes and the target gets pushed out one more year. And there's no explanation why, and even no explanation of the fact that this is happening!! Sorry, but this needs to be called what it is: LYING TO US.
2) Why does Calvin Wallen III's biography indicate that he has an undergraduate degree from Texas A&M that he does not have? He is a confirmed dropout with only a high school diploma. (At least that's more than can be said for Grant Gordon, who is a dropout who doesn't even have a high school diploma; he should be proud at least of having a diploma from junior high school/middle school.)
3) Why does Venturis Therapeutics/CVBT refuse to publicly release its audited financial statements? (We know the answer to this - because the statements will show the company is both insolvent and illiquid.)
4) Why has the company tried to cover up the departure of a series of executives, by refusing to issue statements explaining their departures? We've been left to figure this out ourselves. The good news, however, is that possibly some of them have privately shared the reasons for their departures. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155941891
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.